LO CICERO, MIRKO
LO CICERO, MIRKO
DIPARTIMENTO DI SCIENZE CLINICHE "LUIGI SACCO" (attivo dal 01/01/2002 al 27/04/2012)
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses
2009 S. Rusconi, M. Lo Cicero, O. Viganò, F. Sirianni, E. Bulgheroni, S. Ferramosca, A. Bencini, A. Bianchi, L. Ruiz, C. Cabrera, J. Martinez-Picado, C.T. Supuran, M. Galli
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance
2009 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage
2008 S. Ferramosca, M. Lo Cicero, A.E. Laface, F. Sirianni, E. Cesana, D. Provasi, G. Tiana, M. Galli, M. Moroni, A. Clivio, R.A. Broglia, S. Rusconi
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir
2008 B. Vergani, M. Lo Cicero, O. Viganò, F. Sirianni, S. Ferramosca, P. Vitiello, P. Di Vincenzo, M.P. De Pasquale, M. Galli, S. Rusconi
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro
2007 S. Rusconi, M. Lo Cicero, S. Ferramosca, S. Sirianni, M. Galli, M. Moroni, A.E. Laface, E. Cesana, A. Clivio, G. Tiana, D. Provasi, R.A. Broglia
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro
2007 S. Rusconi, M. Lo Cicero, S. Ferramosca, S. Sirianni, M. Galli, M. Moroni, A.E. Laface, E. Cesana, A. Clivio, G. Tiana, D. Provasi, R.A. Broglia
Efficacy and tolerability of multiple drug therapy in HIV-infected children
2005 A. Viganò, L. Schneider, V. Giacomet, R. Bianchi, M. Lo Cicero, F. Soster, E. Bulgheroni, S. Rusconi
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2]
2005 M. Lo Cicero, E. Bulgheroni, F. Soster, O. Viganò, P. Cicconi, M. Galli, S. Rusconi
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates
2004 E. Bulgheroni, P. Citterio, F. Croce, M. Lo Cicero, O. Viganò, F. Soster, T.C. Chou, M. Galli, S. Rusconi
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects
2002 S. Rusconi, E. Bulgheroni, S. La Seta-Catamancio, F.G. Croce, M. Lo Cicero, P.M. Citterio, M. Galli